Philip F Hughes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3457121/publications.pdf

Version: 2024-02-01

430874 434195 1,131 35 18 31 citations h-index g-index papers 36 36 36 1822 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Discovery of Novel 2-Aminobenzamide Inhibitors of Heat Shock Protein 90 as Potent, Selective and Orally Active Antitumor Agents. Journal of Medicinal Chemistry, 2009, 52, 4288-4305.	6.4	170
2	Fasnall, a Selective FASN Inhibitor, Shows Potent Anti-tumor Activity in the MMTV-Neu Model of HER2 + Breast Cancer. Cell Chemical Biology, 2016, 23, 678-688.	5.2	109
3	Takinib, a Selective TAK1 Inhibitor, Broadens the Therapeutic Efficacy of TNF-α Inhibition for Cancer and Autoimmune Disease. Cell Chemical Biology, 2017, 24, 1029-1039.e7.	5.2	104
4	Application of Chemoproteomics to Drug Discovery: Identification of a Clinical Candidate Targeting Hsp90. Chemistry and Biology, 2010, 17, 686-694.	6.0	79
5	The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and enhance drug binding. Nature Communications, 2016, 7, 12037.	12.8	56
6	Identification of an Allosteric Small-Molecule Inhibitor Selective for the Inducible Form of Heat Shock Protein 70. Chemistry and Biology, 2014, 21, 1648-1659.	6.0	54
7	Optical and Radioiodinated Tethered Hsp90 Inhibitors Reveal Selective Internalization of Ectopic Hsp90 in Malignant Breast Tumor Cells. Chemistry and Biology, 2013, 20, 1187-1197.	6.0	43
8	An inducible heat shock protein 70 small molecule inhibitor demonstrates anti-dengue virus activity, validating Hsp70 as a host antiviral target. Antiviral Research, 2016, 130, 81-92.	4.1	42
9	Fluorescence Linked Enzyme Chemoproteomic Strategy for Discovery of a Potent and Selective DAPK1 and ZIPK Inhibitor. ACS Chemical Biology, 2013, 8, 2715-2723.	3.4	41
10	Synergistic role of HSP90α and HSP90β to promote myofibroblast persistence in lung fibrosis. European Respiratory Journal, 2018, 51, 1700386.	6.7	41
11	A Fluorescent Hsp90 Probe Demonstrates the Unique Association between Extracellular Hsp90 and Malignancy <i>in Vivo</i> . ACS Chemical Biology, 2017, 12, 1047-1055.	3.4	40
12	Cellular fatty acid synthase is required for late stages of HIV-1 replication. Retrovirology, 2017, 14, 45.	2.0	36
13	Targeting therapy-resistant prostate cancer via a direct inhibitor of the human heat shock transcription factor 1. Science Translational Medicine, 2020, 12, .	12.4	36
14	Pharmacological inhibition of TAK1, with the selective inhibitor takinib, alleviates clinical manifestation of arthritis in CIA mice. Arthritis Research and Therapy, 2019, 21, 292.	3.5	31
15	Identification of Hsp90 Inhibitors with Anti-Plasmodium Activity. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	27
16	Genetic and pharmacological validation of TAK1 inhibition in macrophages as a therapeutic strategy to effectively inhibit TNF secretion. Scientific Reports, 2018, 8, 17058.	3.3	27
17	A highly selective Hsp90 affinity chromatography resin with a cleavable linker. Bioorganic and Medicinal Chemistry, 2012, 20, 3298-3305.	3.0	26
18	Targeting Pim Kinases and DAPK3 to Control Hypertension. Cell Chemical Biology, 2018, 25, 1195-1207.e32.	5.2	21

#	Article	IF	CITATIONS
19	Oral Hsp90 inhibitor SNX-5422 attenuates SARS-CoV-2 replication and dampens inflammation in airway cells. IScience, 2021, 24, 103412.	4.1	20
20	Heat shock protein 90-targeted photodynamic therapy enables treatment of subcutaneous and visceral tumors. Communications Biology, 2020, 3, 226.	4.4	18
21	A highly selective inhibitor of interleukin-1 receptor–associated kinases 1/4 (IRAK-1/4) delineates the distinct signaling roles of IRAK-1/4 and the TAK1 kinase. Journal of Biological Chemistry, 2020, 295, 1565-1574.	3.4	17
22	<i>In Vivo</i> Detection of HSP90 Identifies Breast Cancers with Aggressive Behavior. Clinical Cancer Research, 2017, 23, 7531-7542.	7.0	15
23	Leveraging ectopic Hsp90 expression to assay the presence of tumor cells and aggressive tumor phenotypes in breast specimens. Scientific Reports, 2017, 7, 17487.	3.3	15
24	Application of immobilized ATP to the study of NLRP inflammasomes. Archives of Biochemistry and Biophysics, 2019, 670, 104-115.	3.0	13
25	Discovery of novel aminoquinazolin-7-yl 6,7-dihydro-indol-4-ones as potent, selective inhibitors of heat shock protein 90. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 2550-2554.	2.2	12
26	Exploiting heat shock protein expression to develop a non-invasive diagnostic tool for breast cancer. Scientific Reports, 2019, 9, 3461.	3.3	11
27	Development and Efficacy of an Orally Bioavailable Selective TAK1 Inhibitor for the Treatment of Inflammatory Arthritis. ACS Chemical Biology, 2022, 17, 536-544.	3.4	10
28	TAK1 regulates the tumor microenvironment through inflammatory, angiogenetic and apoptotic signaling cascades. Oncotarget, 2020, 11, 1961-1970.	1.8	8
29	Understanding the sources of errors in ex vivo Hsp90 molecular imaging for rapid-on-site breast cancer diagnosis. Biomedical Optics Express, 2021, 12, 2299.	2.9	3
30	Expression of ectopic heat shock protein 90 in male and female primary afferent nociceptors regulates inflammatory pain. Pain, 2022, 163, 1091-1101.	4.2	2
31	HSP90-Specific nIR Probe Identifies Aggressive Prostate Cancers: Translation from Preclinical Models to a Human Phase I Study. Molecular Cancer Therapeutics, 2022, 21, 217-226.	4.1	2
32	Optimizing fluorescently-tethered Hsp90 inhibitor dose for maximal specific uptake by breast tumors. , 2018, , .		1
33	Abstract 4457: Novel fatty-acid synthase inhibitor in combination with platinum-based therapy provides increased tumor killing efficacy in luminal breast murine model. , 2015, , .		0
34	Abstract 2703: Overcoming Lapatinib resistance by the fatty acid synthase inhibitor HS-106., 2015,,.		0
35	Abstract 1859: Hsp90 targeted near infrared molecular imaging to detect mammografically occult invasive lobular breast cancer. , 2017, , .		0